Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy.

Nutrients · 2021 · PMC8001635 · PMID 33802219

Europe PMC DOI

hedged sentences

0.0690

closest p · 1.4× alpha

0.0770

boldest claim

The sentences

did not reach statistical significancep = 0.069so close (0.05 < p ≤ 0.1)

In healthy volunteers ( n = 7), treated with policosanol for 12 weeks, a decrease of PCSK9 levels was observed, but did not reach statistical significance ( p = 0.069) [ 12 ].

also in 111,027 other papers

a strong trendp = 0.077so close (0.05 < p ≤ 0.1)

Difference in PCSK9 levels, from baseline to 8 and 13 weeks, between the supplementation and placebo group showed a strong trend of PCSK9 decrease only in patients with favorable lipids changes in the supplemented group ( p = 0.077).

also in 5,725 other papers

a statistical trendno p-value reported

In a post-hoc explanatory analysis, when the patients were classified as having favorable changes of lipid parameters (LDL-C decrease and HDL-C increase) [ 28 ], a statistical trend towards PCSK9 decrease in the supplemented group as well as PCSK9 increase in the placebo group after 13 weeks of intervention, has been found.

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.